Abstract: Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.
Type:
Grant
Filed:
July 15, 2011
Date of Patent:
April 9, 2019
Assignees:
INNATE PHARMA S.A.S., NOVO NORDISK A/S
Inventors:
Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Joakim Glamann
Abstract: Described herein are isolated bi-specific antigen binding constructs, e.g., antibodies. The bi-specific antigen binding constructs include two antigen binding polypeptide constructs, e.g., a Fab and an scFv. The first antigen-binding polypeptide construct monovalently and specifically binds to extracellular domain 4 (ECD4) of HER2 (human epidermal growth factor receptor 2); the second antigen-binding polypeptide construct monovalently and specifically binds to an extracellular domain (ECD) of HER3 (human epidermal growth factor receptor 3). One antigen binding polypeptide construct is a Fab format and the other antigen binding polypeptide construct is an scFv format. The bi-specific antigen binding constructs includes an Fc having two Fc polypeptides each having a CH3 domain for dimerization. Each Fc polypeptide is linked to the C-terminus of one of the antigen binding polypeptide constructs with or without a linker.
Type:
Grant
Filed:
May 8, 2014
Date of Patent:
March 26, 2019
Assignee:
Zymeworks Inc.
Inventors:
Gordon Yiu Kon Ng, Peter Wing Yiu Chan, Grant Raymond Wickman
Abstract: Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
Type:
Grant
Filed:
January 31, 2017
Date of Patent:
March 19, 2019
Assignee:
TEVA PHARMACEUTICALS PTY LTD
Inventors:
Sarah L. Pogue, David S. Wilson, Anthony Gerard Doyle, Collette Jane Behrens
Abstract: The present disclosure relates to therapies for the treatment of tumor, autoimmune diseases, or other diseases. In some embodiments, the present disclosure can relate to subject-specific selection of humanized antibodies targeting clonal lineage specific marker proteins.
Abstract: This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.
Type:
Grant
Filed:
June 12, 2015
Date of Patent:
February 26, 2019
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
Abstract: The present invention is based, in part, on the discovery of monoclonal antibodies that specifically bind to the cytoplasmic domain of PD-L1 antibodies useful for diagnostic, prognostic, and therapeutic applications, as well as immunoglobulins polypeptides, and nucleic acids thereof.
Type:
Grant
Filed:
October 24, 2014
Date of Patent:
February 12, 2019
Assignees:
Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
Abstract: A method for assessing the risk of potential adverse effects for a human patient receiving a CD19×CD3 bispecific antibody is provided. The method comprises determining the total B count in the patient, and identifying a B cell number indicative of a patient at risk of potential adverse effects from the antibody. The method further provides a dosing schedule for administering the antibody to the patient identified as at risk of potential adverse effects. Also provided is a pharmaceutical package or kit comprising a first dose and a second dose, and optionally a third dose, of the CD19×CD3 bispecific antibody as defined in the methods/dosage regimen of the disclosure.
Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Type:
Grant
Filed:
May 4, 2016
Date of Patent:
January 15, 2019
Assignee:
CytomX Therapeutics, Inc.
Inventors:
Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-1 positive patients.
Type:
Grant
Filed:
March 17, 2016
Date of Patent:
January 8, 2019
Assignee:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Abstract: Microvesicles play essential roles in disease progression. The present invention provides a microvesicle membrane protein and application thereof. Disclosed is a method comprising phosphorylated CSE1L (cellular apoptosis susceptibility protein)- or CSE1L-binding agents for microvesicle isolation, analysis, or binding for disease diagnosis.
Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
Type:
Grant
Filed:
April 29, 2016
Date of Patent:
December 25, 2018
Assignees:
President and Fellows of Harvard College, UCB Biopharma SPRL
Inventors:
Gökhan S. Hotamisligil, Mehmet F. Burak, Feyza Engin, Scott B. Widenmaier, Elisabeth Helen Roberts, Adrian Richard Moore, Carl Brendan Doyle, Ralph Adams, Karine Jeannine Madeleine Hervé, Shauna Mhairi Wales, Kerry Louise Tyson
Abstract: The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-I×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”).
Type:
Grant
Filed:
June 19, 2015
Date of Patent:
December 25, 2018
Assignee:
MacroGenics, Inc.
Inventors:
Ezio Bonvini, Leslie S. Johnson, Kalpana Shah, Ross La Motte-Mohs, Paul A. Moore, Scott Koenig
Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.
Type:
Grant
Filed:
November 14, 2016
Date of Patent:
November 27, 2018
Assignee:
RINAT NEUROSCIENCE CORP.
Inventors:
Weihsien Ho, Jaume Pons, Arvind Rajpal, Pavel Strop
Abstract: Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.
Type:
Grant
Filed:
February 16, 2015
Date of Patent:
November 13, 2018
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Laurence J. N. Cooper, Ana Beatriz Korngold, Brian A. Rabinovich, Harjeet Singh, Simon Olivares
Abstract: The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARS), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties.
Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.
Abstract: The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against a surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against a surface antigen HER2 of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies.
Abstract: The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to MHC class I polypeptide-related sequence A (MICA).
Type:
Grant
Filed:
December 5, 2014
Date of Patent:
October 23, 2018
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Kai W. Wucherpfennig, Glenn Dranoff, F. Stephen Hodi, Bettina Franz, Kenneth F. May, Jr., Christopher Harvey